Insider Selling: Zevra Therapeutics, Inc. (NASDAQ:ZVRA) CEO Sells 61,273 Shares of Stock

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) CEO Neil F. Mcfarlane sold 61,273 shares of the firm’s stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $7.86, for a total value of $481,605.78. Following the completion of the transaction, the chief executive officer now directly owns 222,060 shares of the company’s stock, valued at approximately $1,745,391.60. This trade represents a 21.63 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Zevra Therapeutics Stock Performance

Zevra Therapeutics stock opened at $8.07 on Friday. The company has a debt-to-equity ratio of 0.84, a current ratio of 2.88 and a quick ratio of 2.88. The stock has a fifty day moving average price of $8.22 and a two-hundred day moving average price of $8.04. Zevra Therapeutics, Inc. has a 52-week low of $4.20 and a 52-week high of $9.76. The firm has a market capitalization of $430.78 million, a P/E ratio of -4.10 and a beta of 2.00.

Zevra Therapeutics (NASDAQ:ZVRA) last announced its earnings results on Tuesday, November 12th. The company reported ($0.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.25). Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 159.54%. The business had revenue of $3.70 million during the quarter, compared to analyst estimates of $5.04 million. During the same quarter last year, the business posted ($0.40) earnings per share. As a group, analysts anticipate that Zevra Therapeutics, Inc. will post -1.95 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts recently commented on ZVRA shares. Canaccord Genuity Group reduced their target price on Zevra Therapeutics from $25.00 to $23.00 and set a “buy” rating for the company in a research report on Thursday, November 14th. HC Wainwright reiterated a “buy” rating and set a $20.00 price objective on shares of Zevra Therapeutics in a research note on Wednesday, November 20th. Finally, Cantor Fitzgerald upgraded Zevra Therapeutics to a “strong-buy” rating in a research note on Wednesday, January 29th. Six equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, Zevra Therapeutics has a consensus rating of “Buy” and a consensus target price of $21.57.

Institutional Trading of Zevra Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in ZVRA. Adage Capital Partners GP L.L.C. increased its stake in shares of Zevra Therapeutics by 462.4% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 3,650,000 shares of the company’s stock valued at $30,441,000 after buying an additional 3,001,000 shares in the last quarter. FMR LLC increased its position in Zevra Therapeutics by 282,687.5% in the third quarter. FMR LLC now owns 2,313,202 shares of the company’s stock worth $16,054,000 after purchasing an additional 2,312,384 shares during the period. AIGH Capital Management LLC acquired a new stake in Zevra Therapeutics in the fourth quarter worth about $6,577,000. Stonepine Capital Management LLC acquired a new stake in Zevra Therapeutics in the third quarter worth about $4,858,000. Finally, Vestal Point Capital LP acquired a new stake in Zevra Therapeutics in the third quarter worth about $3,644,000. 35.03% of the stock is currently owned by institutional investors and hedge funds.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.